Richmond Pharmacology Welcomes Back Dr Edward Jackson as Medical Director

Richmond Pharmacology is pleased to announce the return of Dr Edward Jackson, who re-joins the organisation as Medical Director.

Dr Jackson holds both an MBChB and a PhD, with experience across early-phase clinical development. Having previously contributed to a range of clinical trials at Richmond, he returns after a year in the biotech sector, where he focused on oncology and hepatology translational research and advanced his work in diagnostic device development.

In his new role, Dr Jackson will lead the development and expansion of Richmond’s non-interventional study portfolio, drive the adoption of AI technologies across clinical studies, and further strengthen the organisation’s capabilities in rare disease interventional trials.

Dr Jackson commented:

"I’m excited to return to Richmond Pharmacology and contribute to its continued growth in pioneering, data-enabled research. My focus will be on embedding real-world evidence and AI tools into our trial frameworks, especially in the rare disease space, where thoughtful innovation can make a real difference to patients."

Chief Medical Director, Dr Ulrike Lorch, added:

" We’re very pleased to welcome Dr Edward Jackson back to Richmond. His experience in early-phase research and translational science will strengthen our clinical programs, particularly in non-interventional and rare disease studies. We look forward to his contributions as we continue to grow our capabilities in these areas."

With a career built at the intersection of clinical medicine and translational research, Dr Jackson will support the advancement of novel diagnostics and therapies for complex and underserved patient populations.

‍